Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma'. Together they form a unique fingerprint.